Price: $8.1000
$0.07
0.872%
|
Day's High:
| $8.23
| Week Perf:
| -4.59 %
|
Day's Low: |
$ 7.97 |
30 Day Perf: |
-12.72 % |
Volume (M): |
11,257 |
52 Wk High: |
$ 10.13 |
Volume (M$): |
$ 91,185 |
52 Wk Avg: |
$5.11 |
Open: |
$8.02 |
52 Wk Low: |
$3.16 |
|
|
Market Capitalization (Millions $) |
1,784 |
Shares
Outstanding (Millions) |
220 |
Employees |
- |
Revenues (TTM) (Millions $) |
164 |
Net Income (TTM) (Millions $) |
-32 |
Cash Flow (TTM) (Millions $) |
-40 |
Capital Exp. (TTM) (Millions $) |
0 |
Ardelyx Inc
Ardelyx Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for gastrointestinal and cardio-renal diseases. They are committed to providing improved options for patients suffering from chronic and debilitating conditions. Ardelyx's research and development efforts are centered around developing novel oral therapeutics targeting specific biological mechanisms within the gut to address unmet medical needs. Their aim is to develop effective and safe treatments that improve patient outcomes and quality of life.
Company Address: 400 FIFTH AVE. WALTHAM 2451 MA
Company Phone Number: 745-1700 Stock Exchange / Ticker: NASDAQ ARDX
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Product Service News
Published Tue, Mar 12 2024 8:35 PM UTC
In a dynamic and competitive industry like pharmaceuticals, attracting and retaining top-notch talent is crucial for continued success. To this end, Ardelyx, Inc., a prominent biopharmaceutical company, recently announced the issuance of employment inducement grants to non-executive employees. These grants, consisting of stock options and restricted stock units (RSUs), serve...
|
Shares
Published Wed, Dec 20 2023 1:00 PM UTC
WALTHAM, Mass., Dec. 20, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs, continues to make waves in the industry. The company announced on December 18, 2023, that it had granted stock options and restric...
|
Shares
Published Tue, Nov 21 2023 9:02 PM UTC
Ardelyx Employs Stock Options and RSUs to Enlist Top Talent, Intensifying the Quest for Medical Breakthroughs WALTHAM, Mass., Nov. 21, 2023 ? Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative first-in-class medicines to address significant unmet medical needs, has announced the granting of stock...
|
Product Service News
Published Mon, Nov 13 2023 9:02 PM UTC
WALTHAM, Mass., Nov. 13, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a renowned biopharmaceutical company committed to discovering, developing, and commercializing innovative, first-in-class medicines to address unmet medical needs, announced today the departure of Dr. Geoffrey Block from their esteemed Board of Directors. Having served Ardelyx for nearly five years, Dr. ...
|
Shares
Published Thu, Sep 7 2023 12:00 PM UTC
WALTHAM, Mass., Sept. 07, 2023 - Ardelyx, Inc. (Nasdaq: ARDX), a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines that address critical unmet medical needs, recently announced the granting of valuable stock options and restricted stock units (RSUs) to new non-executive employees. These inducements show...
|
Per Share |
Current |
Earnings (TTM) |
-0.12 $ |
Revenues (TTM) |
0.74 $
|
Cash Flow (TTM) |
- |
Cash |
0.84 $
|
Book Value |
0.76 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.12 $
|
Revenues (TTM) |
0.74 $ |
Cash Flow (TTM) |
- |
Cash |
0.84 $
|
Book Value |
0.76 $ |
Dividend (TTM) |
0 $ |
|
|
|
|